A client receiving azathioprine (Imuran) asks why frequent blood tests are required. What is the nurse's best response?

A. Azathioprine does not directly affect the heart’s electrical conduction system and is not associated with causing bradycardia. Monitoring heart rate or rhythm is not a reason for routine laboratory testing when a client is on this medication. Blood tests are primarily used to assess the function of internal organs and the blood-forming system, not cardiac function. B. Azathioprine does not cause fluid loss or significant changes in hydration status. While some medications or medical conditions can lead to dehydration, azathioprine’s main risks involve the immune system and bone marrow suppression. Therefore, dehydration is not a rationale for frequent blood testing in clients taking this drug. C. Azathioprine is not linked to the formation of kidney stones. Renal function may occasionally be monitored in clients with pre-existing kidney disease, but the primary reason for laboratory monitoring is not related to urinary tract complications. D. Azathioprine is an immunosuppressant that works by inhibiting purine synthesis, which interferes with DNA replication in rapidly dividing cells, including immune cells. While this effect is useful in treating autoimmune diseases and preventing organ transplant rejection, it also affects the bone marrow, where blood cells are produced. Suppression of the bone marrow can result in leukopenia (low white blood cell count, increasing infection risk), anemia (low red blood cell count, causing fatigue, pallor, and shortness of breath), and thrombocytopenia (low platelet count, increasing bleeding risk).